The platform has been successfully used by multiple global manufacturers for producing enzymes, peptides, antibody derivatives, and engineered non-natural proteins. It reduces development timelines and costs for manufacturing therapeutics and vaccines, making it well-positioned to meet the growing needs of the pharmaceutical industry. PfÄ“nex Inc., headquartered in San Diego, California, is a leading biotechnology company focused on recombinant protein expression for various applications, including therapeutic proteins, vaccines, research, reagents, and biosimilars. They utilize their cutting-edge PfÄ“nex Expression Technology™, which combines an extensive toolbox of expression components with a high throughput parallel strain screening technology for identifying protein production strains expressing high titers of soluble active protein. Pfenex is developing a pipeline of therapeutic equivalents, vaccines, biologics, and biosimilars, with their lead product candidates being a therapeutic equivalent for osteoporosis treatment and novel anthrax vaccine candidates.